Neuralstem Inc. (CUR) Now Covered by Analysts at Brean Capital
Separately, Roth Capital started coverage on Neuralstem in a research report on Monday, August 29th. They set a buy rating and a $1.20 target price on the stock.
Neuralstem (NASDAQ:CUR) traded up 1.262% during mid-day trading on Tuesday, hitting $0.321. The stock had a trading volume of 175,911 shares. Neuralstem has a 12-month low of $0.19 and a 12-month high of $1.35. The company has a 50-day moving average of $0.29 and a 200-day moving average of $0.39. The stock’s market cap is $36.84 million.
Neuralstem (NASDAQ:CUR) last announced its earnings results on Thursday, August 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. Neuralstem had a negative return on equity of 574.32% and a negative net margin of 173,849.97%. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.50 million. On average, analysts anticipate that Neuralstem will post ($0.17) earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Sabby Management LLC bought a new position in Neuralstem during the second quarter valued at approximately $1,893,000. Vanguard Group Inc. increased its position in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock valued at $984,000 after buying an additional 606,500 shares in the last quarter. Finally, Blair William & Co. IL acquired a new position in shares of Neuralstem during the second quarter valued at about $122,000. 18.20% of the stock is owned by institutional investors.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.